MedTrace Logo

Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects in Fed State

NCT07046715 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-11-17

No results posted yet for this study

Summary

This study is to compare pharmacokinetics and safety profiles of single-administration of DA-5222 and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects in fed state

Conditions

  • Healthy

Interventions

DRUG

DA-5222

single dose administration (DA-5222 one tablet once a day)

DRUG

DA-5222-R1

single dose administration (DA-5222-R1 one tablet once a day)

DRUG

DA-5222-R2

single dose administration (DA-5222-R2 one tablet once a day)

DRUG

DA-5222-R3

single dose administration (DA-5222-R3 one tablet once a day)

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-07
Primary Completion
2025-08-19
Completion
2025-08-19

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07046715 on ClinicalTrials.gov